Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research

Conclusion The high prevalence of comorbidities in patients with stroke indicates the need for therapies in preclinical studies that take into account these comorbidities in order to avoid failures in translation to the patient. Preclinical studies are beginning to evaluate the efficacy of MSC treatment in stroke associated with comorbidities, especially hypertension, for ischemic and hemorrhagic stroke. Regarding aging and diabetes, only ischemic stroke studies have been performed. For the moment, few studies have been performed and contradictory results are being reported. These contradictory results may be due to the use of different stroke and comorbidity models, and to the use of different protocols for administering cell-based therapies. This situation indicates a further need to promote standardization of cell concentration and administration routes. Obesity and hyperglycemia have been completely ignored, although they are frequently present in patients with stroke. For this reason, the role of comorbidities should have a more prominent place in preclinical stroke studies. This will hopefully improve bench-to-bedside translation and identify viable therapeutic options. Author Contributions FL-G and LD wrote the first draft of the manuscript. MG-dF and LO-O wrote sections of the manuscript. BF, GR-A, and ED-T contributed to manuscript revision and read and approved the submitted version. MG-F contributed to the conception of the study, wrote and revised the manuscrip...
Source: Frontiers in Neurology - Category: Neurology Source Type: research